[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,702,200
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,578 M
  • EBITDA $ 4,122 M
  • 60-Month Beta 0.40
  • Price/Sales 5.54
  • Price/Cash Flow 17.91
  • Price/Book 2.54

Options Overview Details

View History
  • Implied Volatility 47.42% (-0.08%)
  • Historical Volatility 22.24%
  • IV Percentile 97%
  • IV Rank 93.03%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 3) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.38
  • Today's Volume 3,681
  • Volume Avg (30-Day) 1,698
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 40,649
  • Open Int (30-Day) 36,091
  • Expected Range 732.86 to 732.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $6.28
  • Number of Estimates 7
  • High Estimate $7.82
  • Low Estimate $4.68
  • Prior Year $6.43
  • Growth Rate Est. (year over year) -2.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
730.90 +0.12%
on 04/28/26
781.21 -6.33%
on 04/01/26
-5.94 (-0.81%)
since 03/27/26
3-Month
727.88 +0.53%
on 03/19/26
815.00 -10.21%
on 02/17/26
-19.36 (-2.58%)
since 01/28/26
52-Week
476.49 +53.58%
on 06/05/25
821.11 -10.88%
on 01/09/26
+120.91 (+19.79%)
since 04/28/25

Most Recent Stories

More News
Regeneron (REGN) Q1 Earnings Report Preview: What To Look For

Regeneron (REGN) Q1 Earnings Report Preview: What To Look For

REGN : 731.77 (-1.70%)
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?

Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there any further upside left in NTLA shares?

REGN : 731.77 (-1.70%)
NTLA : 13.20 (+1.23%)
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

REGN : 731.77 (-1.70%)
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Regeneron will provide  Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid...

REGN : 731.77 (-1.70%)
Otarmeniâ„¢ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

Approval in severe-to-profound and profound  OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting...

REGN : 731.77 (-1.70%)
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin...

SAN.FP : 78.890 (-0.01%)
REGN : 731.77 (-1.70%)
SNY : 45.95 (+0.11%)
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S....

REGN : 731.77 (-1.70%)
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: • BofA Securities Health Care Conference 2026...

REGN : 731.77 (-1.70%)
1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky

1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky

FBNC : 59.67 (-0.03%)
REGN : 731.77 (-1.70%)
WBTN : 12.18 (+2.96%)
Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to announce its fiscal first-quarter earnings this month, and analysts project a low single-digit earnings drop.

XLV : 143.84 (+0.26%)
$SPX : 7,138.80 (-0.49%)
REGN : 731.77 (-1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 765.48
2nd Resistance Point 760.94
1st Resistance Point 752.69
Last Price 731.77
1st Support Level 739.90
2nd Support Level 735.36
3rd Support Level 727.11

See More

52-Week High 821.11
Last Price 731.77
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.